![Petrichor Team](/_next/image?url=https%3A%2F%2Fpetrichor.nyc3.cdn.digitaloceanspaces.com%2Fuploads%2F_1920xAUTO_crop_center-center_none%2FPetrichor-Team.jpg&w=3840&q=75)
We are a team of scientific, medical, financial, technological, and operational leaders built to serve our partners
Our deep understanding of subsector-specific scientific, regulatory, and commercial dynamics underpins everything we do.
![Aaron Kantoff Headshot 2024 01 22 174126 mkgm 2024 01 31 232704 afkv](/_next/image?url=https%3A%2F%2Fpetrichor.nyc3.cdn.digitaloceanspaces.com%2Fuploads%2F_415x552_crop_center-center_none%2FAaron-Kantoff-Headshot_2024-01-22-174126_mkgm_2024-01-31-232704_afkv.jpg&w=3840&q=75)
Aaron Kantoff
Founder, Managing Partner Scion
+
Aaron Kantoff
Founder, Managing Partner Scion
Aaron is a founder and Managing Partner of Scion. He has spent over a decade specializing in founding, building and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Tourmaline Bio (NASDAQ: TRML), where he has been serving since the company’s inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC (NASDAQ: CNTA) and assisted the team with other privately held therapeutics investments. Before joining Medicxi, he was a co-founder and founding board member of RayzeBio (NASDAQ: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY).
From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking.
Aaron received a B.S. in Finance and International Business from NYU Stern’s School of Business.